BACKGROUND & AIMS: Nonalcoholic fatty liver disease is associated with insulin resistance and diabetes. The purpose of this study was to determine the relationship between intrahepatic triglyceride (IHTG) content and insulin action in liver (suppression of glucose production), skeletal muscle (stimulation of glucose uptake), and adipose tissue (suppression of lipolysis) in nondiabetic obese subjects. METHODS: A euglycemic-hyperinsulinemic clamp procedure and stable isotopically labeled tracer infusions were used to assess insulin action, and magnetic resonance spectroscopy was used to determine IHTG content, in 42 nondiabetic obese subjects (body mass index, 36 +/- 4 kg/m(2)) who had a wide range of IHTG content (1%-46%). RESULTS: Hepatic insulin sensitivity, assessed as a function of glucose production rate and plasma insulin concentration, was inversely correlated with IHTG content (r = -0.599; P < .001). The ability of insulin to suppress fatty acid release from adipose tissue and to stimulate glucose uptake by skeletal muscle were also inversely correlated with IHTG content (adipose tissue: r = -0.590, P < .001; skeletal muscle: r = -0.656, P < .001). Multivariate linear regression analyses found that IHTG content was the best predictor of insulin action in liver, skeletal muscle, and adipose tissue, independent of body mass index and percent body fat, and accounted for 34%, 42%, and 44% of the variability in these tissues, respectively (P < .001 for each model). CONCLUSIONS: These results show that progressive increases in IHTG content are associated with progressive impairment of insulin action in liver, skeletal muscle, and adipose tissue in nondiabetic obese subjects. Therefore, nonalcoholic fatty liver disease should be considered part of a multiorgan system derangement in insulin sensitivity.
BACKGROUND & AIMS:Nonalcoholic fatty liver disease is associated with insulin resistance and diabetes. The purpose of this study was to determine the relationship between intrahepatic triglyceride (IHTG) content and insulin action in liver (suppression of glucose production), skeletal muscle (stimulation of glucose uptake), and adipose tissue (suppression of lipolysis) in nondiabetic obese subjects. METHODS: A euglycemic-hyperinsulinemic clamp procedure and stable isotopically labeled tracer infusions were used to assess insulin action, and magnetic resonance spectroscopy was used to determine IHTG content, in 42 nondiabetic obese subjects (body mass index, 36 +/- 4 kg/m(2)) who had a wide range of IHTG content (1%-46%). RESULTS:Hepatic insulin sensitivity, assessed as a function of glucose production rate and plasma insulin concentration, was inversely correlated with IHTG content (r = -0.599; P < .001). The ability of insulin to suppress fatty acid release from adipose tissue and to stimulate glucose uptake by skeletal muscle were also inversely correlated with IHTG content (adipose tissue: r = -0.590, P < .001; skeletal muscle: r = -0.656, P < .001). Multivariate linear regression analyses found that IHTG content was the best predictor of insulin action in liver, skeletal muscle, and adipose tissue, independent of body mass index and percent body fat, and accounted for 34%, 42%, and 44% of the variability in these tissues, respectively (P < .001 for each model). CONCLUSIONS: These results show that progressive increases in IHTG content are associated with progressive impairment of insulin action in liver, skeletal muscle, and adipose tissue in nondiabetic obese subjects. Therefore, nonalcoholic fatty liver disease should be considered part of a multiorgan system derangement in insulin sensitivity.
Authors: Shivakumar Chitturi; Shehan Abeygunasekera; Geoffrey C Farrell; Jane Holmes-Walker; Jason M Hui; Caroline Fung; Rooshdiya Karim; Rita Lin; Dev Samarasinghe; Christopher Liddle; Martin Weltman; Jacob George Journal: Hepatology Date: 2002-02 Impact factor: 17.425
Authors: M Cassader; R Gambino; G Musso; N Depetris; F Mecca; P Cavallo-Perin; G Pacini; M Rizzetto; G Pagano Journal: Lipids Date: 2001-10 Impact factor: 1.880
Authors: Brent A Neuschwander-Tetri; Elizabeth M Brunt; Kent R Wehmeier; Dana Oliver; Bruce R Bacon Journal: Hepatology Date: 2003-10 Impact factor: 17.425
Authors: David E Kelley; Therese M McKolanis; Refaat A F Hegazi; Lewis H Kuller; Satish C Kalhan Journal: Am J Physiol Endocrinol Metab Date: 2003-10 Impact factor: 4.310
Authors: Elisa Fabbrini; Robyn A Tamboli; Faidon Magkos; Pamela A Marks-Shulman; Aaron W Eckhauser; William O Richards; Samuel Klein; Naji N Abumrad Journal: Gastroenterology Date: 2010-05-07 Impact factor: 22.682
Authors: Aviva B Sopher; Adrienne T Gerken; Eun-Ju Lee; William E Blaner; Stefanie Deeds; Dympna Gallagher; Dikoma C Shungu; Xiangling Mao; Abeer Hassoun; Donald J Mc Mahon; Sharon E Oberfield Journal: J Pediatr Endocrinol Metab Date: 2011 Impact factor: 1.634
Authors: Elisa Fabbrini; Faidon Magkos; Caterina Conte; Bettina Mittendorfer; Bruce W Patterson; Adewole L Okunade; Samuel Klein Journal: J Lipid Res Date: 2011-12-05 Impact factor: 5.922
Authors: Naoki Kumashiro; Derek M Erion; Dongyan Zhang; Mario Kahn; Sara A Beddow; Xin Chu; Christopher D Still; Glenn S Gerhard; Xianlin Han; James Dziura; Kitt Falk Petersen; Varman T Samuel; Gerald I Shulman Journal: Proc Natl Acad Sci U S A Date: 2011-09-19 Impact factor: 11.205
Authors: Rebecca J Brown; Areli Valencia; Megan Startzell; Elaine Cochran; Peter J Walter; H Martin Garraffo; Hongyi Cai; Ahmed M Gharib; Ronald Ouwerkerk; Amber B Courville; Shanna Bernstein; Robert J Brychta; Kong Y Chen; Mary Walter; Sungyoung Auh; Phillip Gorden Journal: J Clin Invest Date: 2018-07-16 Impact factor: 14.808